FDA approves Gilead’s HIV injection: “Historic day”

Gilead Sciences’ preventive HIV drug, lenacapavir, was approved on Wednesday by the U.S. Food and Drug Administration (FDA), sparking new hope for finally break...

Large study: The benefits and risks of obesity medications

Medications such as Ozempic can reduce the risk of a range of different diseases and health conditions but also increase the risk of others. This is according t...

US Health Secretary Kennedy dismisses all vaccine experts – assembles new committee

Robert F. Kennedy Jr. has dismissed all 17 members of the CDC’s vaccine advisory panel. A new group of experts will be appointed directly by the Health Secretar...

Improved processes and more

Discover the full potential and benefits.

Compact and leak-tight powerhouse

Media-separated solenoid valve VYKA from Festo is virtually leak-free

Unmatched performance and flexibility in its class

The new ZEISS SPECTRUM family is equipped to be the ideal match from measuring small electronics up to larger housings.

Speed meets precision for high-density components

ZEISS METROTOM 800 320 kV.

Grönt ljus för Gesyntas endometriosstudie i Storbritannien – ”Ett stort steg”

Gesynta Pharma har fått klartecken i Storbritannien för att inleda en fas II-studie med sin läkemedelskandidat inom endometrios.

Quality Assurance for the Highest Medical Standards

Metrology Solutions for Medical Components.

ZEISS presents the "Quality Innovation Days"

The digital event for metrology and software.

The Future of Swedish & Danish Life Science (2026)

Icelandic pharmaceutical company Alvotech to list on Nasdaq Stockholm

One of Iceland's largest companies, the pharmaceutical firm Alvotech, has announced its intention to list on Nasdaq Stockholm.

Positive EMA Decision for BioArctic's New Drug Candidate

Bioarctic's drug candidate for multiple system atrophy, exidavnemab, is recommended to be classified as an orphan drug, according to the European Medicines Agency (EMA).

Peter Hovstadius är ny medicinsk chef på Lif

Läkaren Peter Hovstadius har utsetts till Chief Medical Officer på branschorganisationen Lif – de forskande läkemedelsföretagen.

Reveal the Structures and Functions of Life

Super-resolution microscopes from ZEISS.

Her company is developing a new tablet form obesity drug

, but not the same side effect profile,’’ company founder Dorte X Gram said in an interview with Life Science Sweden.

Genterapi gav hörsel till barn med medfödd dövhet – elva av tolv förbättrades

Elva av tolv barn med medfödd dövhet uppvisade förbättringar i en studie där Regenerons genterapi mot ärftlig hörselnedsättning prövades. Nu planerar det amerik...

Ny rapport: Små bolag lyfter svensk läkemedelsutveckling

Sveriges läkemedelsforskning fortsätter att gå starkt framåt, enligt en ny rapport från Sweden Bio. Landets projekt blir både fler och vassare – med småbolagen i spetsen.

Rise and Scantox cease conducting animal testing in Stockholm

Access to in vivo toxicology services is significantly decreasing in the Stockholm area as Rise shuts down animal testing and Scantox reorganizes. ”The costs ar...

Venomaid's rapid test aims to find the right snake bite treatment

Every six seconds, someone on our planet suffers a snake bite, and each time, a race against the clock begins. What kind of snake was it, and which antivenom ca...

How to Assure Quality within R&D Medical Devices

Free webinar on June 3rd, 2025, 9:00 - 9:45 AM CEST and 5:00 - 5:45 PM CEST.

AstraZeneca´s Trixeo approved in the UK using propellant with near-zero Global Warming Potential

AstraZeneca has received approval in the United Kingdom for its inhaled respiratory medicine Trixeo Aerosphere with a new propellant that is reported to reduce ...

The scientist behind Novo Nordisk's obesity success: “I never stopped believing in GLP-1”

It took several years of failures in GLP-1 before Lotte Bjerre Knudsen and her colleagues found the right path – but when they did, it was a true breakthrough. ...

Donanemab godkänns i Storbritannien – men anses för dyrt för skattebetalarna

Eli Lillys alzheimerläkemedel donanemab godkänns i Storbritannien – men lär ändå inte bli tillgängligt för vanliga patienter. Orsaken är att behandlingen bedöms...